Skip to Main Navigation

How to End the COVID-19 Pandemic by March 2022 (English)

How can the world reach herd immunity against COVID-19 before the second anniversary of the pandemic, or March 2022? A study of vaccine demand and supply answers this question. A target of vaccinating 60 percent of the population in each country by March 2022 is likely sufficient to achieve worldwide herd immunity under a baseline scenario with limited mutation. Achieving this target appears feasible given stated production capacity of vaccine manufacturers and the pace of current and historical vaccination campaigns. Considering existing pre-purchase contracts for vaccines, achieving this target requires addressing a procurement gap of just 350 million vaccine courses in low- and middle-income countries. Immediate additional donor funding of about $4 billion or in-kind donations of excess orders by high-income countries would be sufficient to close this gap. There are additional challenges along the path to achieving world-wide herd immunity---including supply chain issues, trade restrictions, vaccine delivery, and mutations. Overall however, this analysis suggests multilateral action now can bring an end to the acute phase of the pandemic early next year.

Details

  • Author

    Agarwal,Ruchir, Reed,Tristan

  • Document Date

    2021/04/15

  • Document Type

    Policy Research Working Paper

  • Report Number

    WPS9632

  • Volume No

    1

  • Total Volume(s)

    1

  • Country

    World,

  • Region

    The World Region,

  • Disclosure Date

    2021/04/15

  • Disclosure Status

    Disclosed

  • Doc Name

    How to End the COVID-19 Pandemic by March 2022

  • Keywords

    unequal distribution; international development finance; Vaccines; vaccine need; material need; investment need; production capacity; billion people; availability of vaccine; vaccine production capacity; quantities of vaccine; concerted global action; supply of vaccine; parameter of interest; increase in capacity; terms of policy; Research Support; public health authority; source of vaccine; development of vaccine; total world population; supply chain; raw material; vaccine coverage; vaccine delivery; available data; vaccination campaign; acute phase; grant funding; vaccination rate; emergency use; export restrictions; production target; global health; vaccine supply; clinical trial; vaccination coverage; trade restriction; upper bind; adult population; Learning and Innovation Credit; existing vaccine; regulatory authority; government action; large population; strategic reserve; public domain; Donor Commitment; take time; government subsidy; donor funding; press release; natural immunity; steady state; aggregate supply; population survey; higher-income countries; small country; missing data; oil exporter; cross-country variation; behavioral change; recent studies; local supply; host population; commercial license; secondary infections; market capacity; unit price; value use; manufacturing process; global supply; host cell; genetic material; available capacity; molecular biology; dry ice; vaccine manufacturer; blood clots; vaccine research; alternative scenarios; new infections; global spread; cold-chain equipment; vaccine candidate; allocation rule; Trade Policy; Trade Policies; random survey; eligible individual; age distribution; several countries; youth population; children of ages; minimum age; demographic challenge; increased speed; domestic production; production constraint; information campaign; technology platform; regulatory approval; local condition; remote area; baseline scenario; downside scenario; blood donors; new cases; adjustment process; Health ministries; downside risk; biological threat; news source; production line; booster shot; necessary investment; price mechanism; quality information; capacity constraint; expanding investment; state intervention; protective equipment; legal authority; industrial base; domestic capacity; packaging material; short supply; manufacturing facility; produce trading; block exports; chief scientist; secure supply; safety datum; multilateral agency; global surveillance; fast delivery; multilateral cooperation; cross-border trade; increased demand; institutional framework; development policy; executive board; research assistance; existing capacity; production bottleneck; vaccination drive; simple model; funding gap; standard approach; short-term target; market price; global pandemic; large outbreak; binding constraint; open access; policy priority; multilateral action; market size

Downloads

COMPLETE REPORT

Official version of document (may contain signatures, etc)

  • Official PDF
  • TXT*
  • Total Downloads** :
  • Download Stats
  • *The text version is uncorrected OCR text and is included solely to benefit users with slow connectivity.

Citation

Agarwal,Ruchir Reed,Tristan

How to End the COVID-19 Pandemic by March 2022 (English). Policy Research working paper,no. WPS 9632,COVID-19 (Coronavirus) Washington, D.C. : World Bank Group. http://documents.worldbank.org/curated/en/181611618494084337/How-to-End-the-COVID-19-Pandemic-by-March-2022